More articles from Therapeutic Agents: Biological: Poster Presentations - Proffered Abstracts

Abstract B116: Optimizing a CD71-targeting Probody drug conjugate (PDC) for activity in multiple solid tumor and lymphoma models and for tolerability in nonhuman primates
Shweta Singh, Laura Serwer, Niharika Chauhan, Amy DuPage, Michael Krimm, Ken Wong, Yuanhui Huang, Andrew Jang, Eric Ureno, Adam Miller, Sarah Patrick, Shanti Duvur, Fritz Buchanan, Matthew M. Ravn, Rob Leanna, Ilaria Badagnani, Tracy Henriques, Shouchun Liu, Claus Krebber, Sridhar Viswanathan, Jennifer Richardson, Susan Morgan-Lappe, Michael Kavanaugh

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B116; DOI: 10.1158/1535-7163.TARG-17-B116
Abstract B117: Phase II study of brentuximab vedotin and bevacizumab in GCT
Shilpa Gupta, Benjamin L. Maughan

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B117; DOI: 10.1158/1535-7163.TARG-17-B117
Abstract B111: Characterization of APVO436, a bispecific anti-CD123 x anti-CD3 ADAPTIR™ molecule for redirected T-cell cytotoxicity, in preclinical models of AML and nonhuman primates
Michael R. Comeau, Robert E. Miller, Jeannette Bannink, Starrla Johnson, Robert Bader, Rebecca Gottschalk, Lynda Misher, Danielle Mitchell, Lara Parr, Melissa DeFrancesco, David Bienvenue, Catherine J. McMahan, Gabriela H. Hoyos, Jane A. Gross

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B111; DOI: 10.1158/1535-7163.TARG-17-B111
Abstract LB-B26: Novel eIF4A inhibitors target both cellular and microenvironment components in pancreatic ductal adenocarcinoma
Maryam Safari, Yu Ri Kim, Changchun Deng, Susan E. Bates

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) LB-B26; DOI: 10.1158/1535-7163.TARG-17-LB-B26
Abstract B112: Development and preclinical evaluation of a novel BET inhibitor FF-1027T
Keiko Makita, Kazunori Saeki, Tadashi Tanaka, Yasutomo Kawanishi, Toshifumi Kimura, Shinichi Watanabe, Chihaya Kakinuma, Shinji Hagiwara, Yasuhiro Shimada

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B112; DOI: 10.1158/1535-7163.TARG-17-B112
Abstract LB-B24: Targeting transcriptional addiction for the treatment of TSC
Mahsa zarei, Heng Du, Rachel E. Yan, Yubao Wang, Thingu Zhang, John M. Asara, David J. Kwiatkowski

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) LB-B24; DOI: 10.1158/1535-7163.TARG-17-LB-B24
Abstract B115: MORAb-202: a folate receptor alpha (FRA)-targeting antibody-drug conjugate, exhibiting targeted antitumor activity and bystander elimination of cancer-associated fibroblasts
Katherine A. Rybinski, Christopher Maddage, Xin Cheng, Earl Albone, Luigi Grasso, Keiji Furuuchi, Toshimitsu Uenaka

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B115; DOI: 10.1158/1535-7163.TARG-17-B115
Abstract B106: Antibody-drug conjugates targeted at human aspartyl (asparaginyl) β-hydroxylase
Kanam Malhotra, Susan Walker, Chen Fang, Karamveer Birthare, Michael S. Lebowitz, Steven Fuller, Muctarr Sesay, Hossein A. Ghanbari

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B106; DOI: 10.1158/1535-7163.TARG-17-B106
Abstract B104: A therapeutic antibody candidate against the broadly expressed Tn and STn carbohydrate cancer antigens
G Jonah Rainey, Ritsuko Sawada, Toni Jun, Aleksandra Marinkovic-Petrovic, Ayesha Kahn, Wolfgang Scholz, Paul W. Maffuid

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B104; DOI: 10.1158/1535-7163.TARG-17-B104
Abstract B108: Antitumor efficacy of EGFR antibody necitumumab and dual PI3K/mTOR inhibitor (LY3023414) in preclinical tumor models
Maxine A. Melchior, Xuemei Guo, Gregory P. Donoho, Philip W. Iversen, Thompson N. Doman, Manisha Brahmachary, Xueqian Gong, Gerald E. Hall, Jason R. Manro, Yung-mae M. Yao, Sean Buchanan, Tod Smeal, Michael D. Kalos, Ruslan D. Novosiadly

Molecular Cancer Therapeutics Jan 2018, 17 (1 Supplement) B108; DOI: 10.1158/1535-7163.TARG-17-B108

Main menu

User menu

Search

More articles from Therapeutic Agents: Biological: Poster Presentations - Proffered Abstracts

Pages

Articles

Info for

About MCT